| Identification | Back Directory | [Name]
IRAK-1/4 INHIBITOR I | [CAS]
509093-47-4 | [Synonyms]
CS-1991
IRAK-1/4 Inhibitor
IRAK-1/4 INHIBITOR I
IIRAK-1-4 Inhibitor I
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor
N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole
N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide
1-(2-(4-Morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole
InSolution? Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor
3-Nitro-N-(1-(2-morpholin-4-ylethyl)-1H-benzimidazol-2-yl)benzamide
N-(1-(2-morpholinoethyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide
N-[1-[2-(4-Morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitrobenzamide
BenzaMide, N-[1-[2-(4-Morpholinyl)ethyl]-1H-benziMidazol-2-yl]-3-nitro-
IRAK-1-4 INHIBITOR I ;INTERLEUKIN-1 RECEPTOR-ASSOCIATED-KINASE-1/4 INHIBITOR
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor - CAS 509093-47-4 - Calbiochem
InSolution Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor - CAS 509093-47-4 - Calbiochem
N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole, 1-(2-(4-Morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole | [Molecular Formula]
C20H21N5O4 | [MDL Number]
MFCD09752602 | [MOL File]
509093-47-4.mol | [Molecular Weight]
395.41 |
| Chemical Properties | Back Directory | [density ]
1.40 | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥5mg/mL | [form ]
Yellow crystalline solid | [pka]
11.54±0.43(Predicted) | [color ]
off-white to light yellow | [InChI]
InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26) | [InChIKey]
QTCFYQHZJIIHBS-UHFFFAOYSA-N | [SMILES]
C(NC1N(CCN2CCOCC2)C2=CC=CC=C2N=1)(=O)C1=CC=CC([N+]([O-])=O)=C1 |
| Hazard Information | Back Directory | [Uses]
IRAK-1/4 Inhibitor (interleukin-1 receptor-associated kinases) are important mediators in signal transduction of TIR family members. This regulation protects against the development of cancers and other diseases. | [Biological Activity]
irak-1-4 inhibitor i is an inhibitor of both irak-1 and irak-4 with ic50 values of 0.3μm and 0.2μm , respectively [1].il-1 receptor-associated kinases play important roles in signal transduction. there are totally four members of the iraks, they are irak-1, irak-2, irak-m and irak-4. irak-4 can activate nf-κb and mapk pathways and it is shown that the inhibition of irak-4 can be an anti-inflammatory therapy. irak-1-4 inhibitor i is an analog of an initial irak-4 inhibitor hit, which is screened out from a small molecule li brary against irak-4. with the less basic n-ethylenemorpholine moiety, irak-1-4 inhibitor i has a higher potency than other analogs. additionally, it does not show any cytotoxicity in a 72 h proliferation assay in hela cells(ed50 >30μm) [1]. | [Biochem/physiol Actions]
IRAK1 overexpression leads to the development of head and neck squamous cell carcinoma (HNSCC). Therefore, IRAK-1/4 inhibitor I might be a potential therapeutic for HNSCC tumors. Various experimental studies states that IRAK-1/4 inhibitor might have a potential to exhibit?inhibitory effects on the nuclear factor (NF)-κB signaling pathway. | [storage]
Store at -20°C | [References]
[1] jay p. powers, shyun li, juan c. jaen, jinqian liu, nigel p. c. walker, zhulun wang and holger wesche. discovery and initial sar of inhibitors of interleukin-1 receptor-associated kinase-4. bioorganic & medicinal chemistry letters. 2006, 16: 2842–2845. |
|
| Company Name: |
Sigma-Aldrich
|
| Telephone: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|